Alexion Buys Out Portola, But Analysts Don’t See Value
Executive Summary
The acquisition brings Alexion the bleeding reversal agent Andexxa, which execs called a synergistic addition to its portfolio – but analysts are struggling to see the match with Alexion’s chronic rare disease therapies.
You may also be interested in...
PhaseBio’s Bentracimab Could Benefit From Growth In Brilinta Demand
The antiplatelet drug-reversal agent could see uptake grow in tandem with that of Brilinta, but there is a history of drugs in similar indications underperforming on the market.
Twitchy Times At GSK As Activist Investor Takes Big Stake
GlaxoSmithKline's market value has slipped in the past three years and the number of failures in the clinic have grown. The major's leadership will be casting nervous glances towards a major shareholder that has a reputation for aggressive restructuring calls.
AZ's Alexion Acquisition Looks Astute Bit Of Business
Some analysts are suggesting that AstraZeneca is getting hold of a "scarce and high-quality asset" in Alexion for a very reasonable price and shareholders could demand more than the $175 per share offer on the table.